Ramy A.  Mahmoud net worth and biography

Ramy Mahmoud Biography and Net Worth

COO of OptiNose
Dr. Mahmoud joined his partner, Peter Miller, in the start-up of Optinose and its US subsidiary in 2010, taking the role of President and Chief Operating Officer and sharing responsibility for leading all aspects of the Company. This includes overall corporate strategy; finance; scientific activities inclusive of product R&D, manufacturing and supply chain; commercial development; and business development.

Prior to Optinose, Dr. Mahmoud spent 14 years at Johnson & Johnson where he was Chief Medical Officer and a member of the Global Management Board of the Ethicon group of companies. During his Johnson & Johnson tenure, he also held senior roles in the Pharmaceutical sector, and in addition to management board responsibilities at several operating companies, he led a range of functions in both R&D and commercial organizations. Dr. Mahmoud participated in the development, launch and/or commercialization of dozens of pharmaceutical and medical device products spanning multiple therapeutic categories.

Earlier in his career, Dr. Mahmoud served 10 years on active duty and an additional 10 reserve years in the United States Army, earning the rank of Lieutenant Colonel and acting at times as a battalion surgeon or flight surgeon. He received numerous commendations and decorations for his service. During this time, he held various patient care, research and academic positions, culminating as head of the Department of Epidemiology at the Walter Reed Army Institute of Research and as inaugural leader of a policy research and analysis activity in support of the Assistant Secretary of Defense (Health Affairs).

Over the span of his time in public service and in business leadership, Dr. Mahmoud has become an accomplished international scientist, making hundreds of scientific presentations, publishing many peer-reviewed papers and textbook chapters and serving as a scientific reviewer for a number of journals and textbooks.

Dr. Mahmoud earned a Master’s degree with a focus in healthcare management and policy from Harvard, an MD from the first Honors Program in Medical Education at the University of Miami and board certifications in both Public Health/Preventive Medicine and in Internal Medicine. He holds certificates from the Program in Clinical Effectiveness (Harvard Medical School) and in Advanced Tropical Medicine (Walter Reed). Dr. Mahmoud has been and remains involved with a number of professional societies.

What is Ramy A. Mahmoud's net worth?

The estimated net worth of Ramy A. Mahmoud is at least $1.97 million as of March 18th, 2024. Dr. Mahmoud owns 1,331,278 shares of OptiNose stock worth more than $1,970,291 as of March 28th. This net worth evaluation does not reflect any other assets that Dr. Mahmoud may own. Additionally, Dr. Mahmoud receives an annual salary of $731,590.00 as COO at OptiNose. Learn More about Ramy A. Mahmoud's net worth.

How old is Ramy A. Mahmoud?

Dr. Mahmoud is currently 59 years old. There are 4 older executives and no younger executives at OptiNose. Learn More on Ramy A. Mahmoud's age.

What is Ramy A. Mahmoud's salary?

As the COO of OptiNose, Inc., Dr. Mahmoud earns $731,590.00 per year. Learn More on Ramy A. Mahmoud's salary.

How do I contact Ramy A. Mahmoud?

The corporate mailing address for Dr. Mahmoud and other OptiNose executives is 1020 STONY HILL ROAD SUITE 300, YARDLEY PA, 19067. OptiNose can also be reached via phone at (267) 364-3500 and via email at [email protected]. Learn More on Ramy A. Mahmoud's contact information.

Has Ramy A. Mahmoud been buying or selling shares of OptiNose?

Ramy A. Mahmoud has not been actively trading shares of OptiNose during the last quarter. Learn More on Ramy A. Mahmoud's trading history.

Who are OptiNose's active insiders?

OptiNose's insider roster includes Victor Clavelli (Insider), Keith Goldan (CFO), Ramy Mahmoud (COO), Michael Marino, III (Insider), and Peter Miller (CEO). Learn More on OptiNose's active insiders.

Are insiders buying or selling shares of OptiNose?

In the last year, insiders at the sold shares 10 times. They sold a total of 126,729 shares worth more than $184,454.09. The most recent insider tranaction occured on March, 18th when CAO Anthony J Krick sold 2,345 shares worth more than $4,408.60. Insiders at OptiNose own 2.2% of the company. Learn More about insider trades at OptiNose.

Information on this page was last updated on 3/18/2024.

Ramy A. Mahmoud Insider Trading History at OptiNose

See Full Table

Ramy A. Mahmoud Buying and Selling Activity at OptiNose

This chart shows Ramy A. Mahmoud's buying and selling at OptiNose by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

OptiNose Company Overview

OptiNose logo
OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device. OptiNose, Inc. has a license agreement with Currax Pharmaceuticals LLC for the commercialization of Onzetra Xsail; and Orexia Therapeutics to develop, manufacture, import, and sale products containing orexin receptor agonist and/or orexin receptor positive modulator molecules for the treatment, diagnosis, or prevention of human diseases or conditions associated primarily with orexin receptor agonism and orexin receptor positive modulation. The company was founded in 2000 and is headquartered in Yardley, Pennsylvania.
Read More

Today's Range

Now: $1.48
Low: $1.43
High: $1.49

50 Day Range

MA: $1.53
Low: $1.21
High: $1.94

2 Week Range

Now: $1.48
Low: $0.90
High: $2.10

Volume

400,436 shs

Average Volume

560,251 shs

Market Capitalization

$166.72 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A